John W. Ostrominski

3 weeks ago | pharmacytimes.com | Alexandra Gerlach |John W. Ostrominski

In an interview with Pharmacy Times®, John Ostrominski, MD, fellow of Cardiovascular Medicine and Obesity Medicine at Brigham and Women's Hospital, discusses findings on finerenone (Kerendia; Bayer), highlighting its effectiveness in reducing cardiovascular death and worsening heart failure (HF) events while maintaining a favorable safety profile.

3 weeks ago | ajmc.com | Giuliana Grossi |John W. Ostrominski

Patients with heart failure (HF) and chronic kidney disease face a heightened risk of disease progression, yet treatment decisions in this population often require careful balancing of efficacy and safety concerns, John W. Ostrominski, MD, fellow in Cardiovascular Medicine and Obesity Medicine at Brigham and Women’s Hospital and Harvard Medical School, explained in an interview at the American College of Cardiology 2025 Annual Scientific Session (ACC.25).

Jan 20, 2025 | thelancet.com | John W. Ostrominski |Vanita R. Aroda

References1. World Obesity FederationWorld Obesity Atlas 20242. GBD 2021 Diabetes CollaboratorsGlobal, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021Lancet. 2023; 402:203-2343. Savarese, G ∙ Becher, PM ∙ Lund, LH ∙ et al. Global burden of heart failure: a comprehensive and updated review of epidemiologyCardiovasc Res. 2022; 118:3272-32874. Jackson, AM ∙ Rørth, R ∙ Liu, J ∙ et al.

Nov 8, 2024 | onlinelibrary.wiley.com | John W. Ostrominski |Petar Seferovic |Serbian Academy |Senthil Selvaraj

Corresponding Author Senthil Selvaraj Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA Duke Molecular Physiology Institute, Durham, NC, USA Corresponding author. Duke Molecular Physiology Institute, Duke University School of Medicine, 300 N Duke St, Durham, NC 27701, USA. Email: [email protected] for more papers by this author

Oct 22, 2024 | jacc.org | Scott Solomon |John W. Ostrominski |Xiaowen Wang |Sanjiv Shah

Introduction Abnormalities of cardiac structure and function are common in heart failure (HF) and remain powerful predictors of HF onset and progression.1-4 Increasing evidence indicates that obesity is a major driver of both adverse cardiac remodeling and HF, particularly heart failure with preserved ejection fraction (HFpEF).5-10 Indeed, obesity-related HFpEF is now recognized as a widely prevalent and high-risk phenotype within the broader HFpEF spectrum,11,12 characterized by...